Once a death sentence, thyroid storm is now largely survivable. Here’s a look at what’s new in the prevention, recognition, and treatment of the most frightening endocrine emergency in history.
Autoimmune Diagnostics

For nearly 30 years, KRONUS has provided specialized immunoassay test kits to medical professionals at the world’s most respected laboratory facilities. Our current product offering encompasses test kits for measurement of the following:

**NEUROIMMUNOLOGY**
Acetylcholine Receptor Antibody (AChRAb):
- Binding Antibody
- Blocking Antibody
Voltage-Gated Calcium Channel Antibody (VGCCAb)

**ISLET CELL AUTOIMMUNITY**
Glutamic Acid Decarboxylase Antibody (GADAb)
IA-2 Autoantibody (IA-2Ab)
Insulin Autoantibody (IAA)

**THYROID**
Thyroglobulin Antibody (TgAb)
Thyroid Peroxidase Antibody (TPOAb)
TSH Receptor Antibody (TRAb)
Serum Thyroglobulin (Tg)

**ADRENAL AUTOIMMUNITY**
21-Hydroxylase Antibody (21-OHAb)

**ALSO AVAILABLE FOR RESEARCH APPLICATIONS**
- Interferon-Omega Autoantibody (IFN-ωAb)†
- Aquaporin-4 Autoantibody (AQP4Ab)†
- Voltage-Gated Potassium Channel Antibody (VGKCAb)†
- Titin Antibody (TitinAb)†
- Zinc Transporter 8 Antibody (ZnT8Ab)†
- GAD/IA-2 Antibody Screent†

† For Research Use Only. Not for use in diagnostic procedures.

To obtain additional information on KRONUS® unique line of laboratory test kits, please call us toll-free at 800 4 KRONUS or email us at kronus@kronus.com.
COVER STORY

Gathering Storm
By Kelly Horvath
One of the most confounding endocrine emergencies in history, thyroid storm is no longer a death sentence. Here’s a look at what’s new on the horizon in the prevention, recognition, and treatment of this once fatal malady.

Depression, Distress, and Diabetes
By Terri D’Arrigo
When a diabetic patient is also dealing with depression, there are myriad issues to consider for both the physician and the patient. Everything from diabetes distress and medications to alcohol consumption can affect both conditions.

One for the Record Books
By Derek Bagley
ICE/ENDO 2014 was definitely one for the record books: It was our highest attended annual meeting in history with over 10,000 attendees descending on Chicago from all over the world. If you missed it you’re in luck, we’ve provided some research highlights from the data that was presented.

Pregnant Pause
By Melissa Mapes
The “Plan B” contraceptive pill is the most affordable and convenient form of emergency contraception for women in the U.S., yet it has a remarkable failure rate in larger women.

Lighten the Load
By Melissa Mapes
A typical research lab uses a lot of energy on any given day, but there are simple steps you can take to “green” your lab.
This past year, in my president-elect role, I gained a deeper appreciation of the past presidents’ extraordinary vision and leadership that have contributed to the outstanding success of the Society over the years. I would specifically like to thank past-president Bill Young and immediate past-president Teresa Woodruff for their commitment and devotion to the Endocrine Society.

I would like to congratulate Teresa Woodruff, the Annual Meeting Steering Committee (AMSC), and staff for making ICE/ENDO 2014 a record-breaking meeting in all areas. This meeting had the highest number of scientific registrants and overall attendees in ICE and ENDO history. More than 10,000 registrants representing 96 countries attended the meeting. The Society received more than 3,200 scientific abstracts, which is another record-breaking number. And not only did we break all our previous records, the scientific program was outstanding as many of you can attest.

I am hopeful that ENDO 2015 will be another exceptional meeting both in attendance and content.

One of my first tasks as president-elect was to appoint the AMSC chairs for the ENDO 2015 meeting. With ENDO 2015 moving to March, the planning timeline for the meeting has been compressed this year. The AMSC chairs and committee have been selected and include Mathew Ringel as overall chair and Sue Moenter, Marc-Andre Cormier, and Carol Wysham as basic, clinical science, and clinical practice co-chairs, respectively. The AMSC has already met and developed an outstanding scientific program, which will be featured in more detail in next month’s Endocrine News. As many of you know, the registration for ENDO 2015 has already opened. Please mark your calendars for the ENDO 2015 dates: Thursday, March 5 to Sunday, March 8, 2015. Also note that the abstract submission will launch on September 17, 2014, with a closing date of November 11, 2014.

The new spring timing of ENDO ensures that endocrine science will receive extra attention ahead of the summer and fall meetings. The best clinical trials will be showcased in special sessions. Visit www.endo2015.org, and click on the “Abstracts and Awards” button to learn more about the exceptional benefits of submitting your clinical trial abstract to ENDO including options for fast-track publication and focused media attention.

As many of you have heard me mention before, my biggest passion and the main focus of my presidential year is to empower the next generation of endocrinologists. I have briefly discussed some of the plans and initiatives that are being considered to create innovative programs that enhance the recruitment, retention, and development of early-career endocrinologists beyond their training completion. This focus influenced an additional task as president-elect, the appointment of committee members. Much effort was devoted to the identification and appointment of next-generation members, a process that worked out well.

The Society’s awards program is an important way to recognize and honor our outstanding members. Your input is vital, and I would encourage you and your colleagues to submit your nominations starting next month. Each year, the Endocrine Society presents awards totaling over half a million dollars to foster achievement and recognize excellence in endocrine science and medicine. From undergraduate students to those in established careers, the awards recognize all three constituencies; basic researchers, clinical researchers, and clinical practitioners. In late September, the Society will begin the 2015 awards season with calls for applications for the numerous Society trainee and early-career awards and travel grants. In 2014, trainee abstract awards and travel grants and research fellowships were awarded to nearly 500 trainees and early-career professionals. The details of these awards, including application requirements and submission deadlines for 2015, are on the Society’s website, under Awards tab.

I am beginning my presidency full of energy, optimism, and fully committed to the Endocrine Society. If you have any questions or comments, feel free to contact me at president@endocrine.org. I look forward to a productive and successful year for the Endocrine Society.

Richard J. Santen, MD
President, Endocrine Society
Our cover story this month, “Gathering Storm” (p. 10), details one of the most frightening endocrine emergencies physicians are faced with, the thyroid storm. At one time, this confounding condition was a death sentence. Fortunately, thanks to research and a better understanding of just exactly what thyroid storm is, it now has a survival rate between 80% and 100%. Difficult to diagnose and tricky to treat, this disorder still has no definitive cause, but according to Colonel Henry B. Burch, MD, professor of medicine and chair of the Endocrinology Division of the Uniformed Services University of the Health Sciences, in Bethesda, Md., the key to a patient’s survival is simply “making the diagnosis.”

Terri D’Arrigo writes on another topic that is all too common: treating diabetes in patients who are also suffering from depression. In “Depression, Distress, and Diabetes” (p. 16), Jeffrey S. Gonzales, PhD, associate professor, Department of Medicine, Department of Epidemiology and Population Health, Albert Einstein College of Medicine in New York, says that “even if you’re a very sensitive endocrinologist who knows about depression and wants to get your patient appropriate care, insurance plans may separate mental health benefits from diabetes treatment [in a way that makes teamwork among clinicians difficult]. It’s like chopping people up into different diseases.”

As the obesity epidemic continues its rampage, it’s amazing to see how it affects so many aspects of daily life, even how it impacts pregnancy and birth control. In “Pregnant Pause” on page 24, Melissa Mapes writes about how the over-the-counter female oral contraceptive levonorgestrel — or “Plan B” — has an unusually high failure rate in overweight women. Since this is currently the only affordable emergency contraception available for women over the counter, heavier women might have to seek out a “Plan C.”

If you were fortunate enough to be in Chicago for ICE/ENDO 2014 then you saw firsthand the voluminous amount of research that was presented. On page 20, associate editor Derek Bagley gives an overview of some of the data presented at the conference. From studies on the burgeoning epidemics of diabetes and obesity to new findings on hormones and pregnancy and endocrine-disrupting chemicals, clinicians from all corners of the field of endocrinology gave some compelling presentations. As a bonus, it was a great way for me to find ideas for 2015, which is closer than you think!

Speaking of 2015, if you have any story ideas or topics you’d like to see covered in Endocrine News, don’t hesitate to drop me a line at mnewman@endocrine.org. EN
Studies on rats have shown that endocrine-disrupting chemicals (EDCs) impact not only future generations, but also how these descendants respond to stress during adolescence. A new study, published in the journal Endocrinology, has revealed that the sexes differ profoundly in these effects. That is, females with a history of exposure respond very differently to stress and exhibit phenotypes that are much more compromised than males.

Researchers led by David Crews, PhD, of the University of Texas at Austin, wrote that the legacy of exposures to EDCs “has permanently altered the present and future health of humans and wildlife.” The paper makes the distinction between “context-dependent” epigenetic modifications, which are not heritable because the germ cells are not affected, and “germline-dependent” epigenetic modifications, which “manifest each generation even in the absence of the causative agent.” They wrote: “This is the case for several EDCs, notably, vinclozolin, bisphenol A, and tributyltin. Such transgenerational modifications affect all levels of biological organization, from gene regulation to behavioral interactions of conspecifics.”

“I have shown previously the transgenerational effects of EDCs on behavior of the descendant generations (F3), (Crews et al. PNAS, 2007),” Crews, says. “More recently, this was extended to a novel two-hit, three-generations apart model to demonstrate how restraint stress experienced during adolescence of the F3 descendants changes their physiology, neural metabolism, and gene expression in adulthood.”

Crews and his team focused on vinclozolin, a commonly used fungicide with demonstrated anti-androgenic properties. They used the two-hit, three-generations apart model, testing how F3 descendants of rats given in utero exposures to vinclozolin reacted to stress in their own lives, focusing on sexually dimorphic phenotypic outcomes. The scientists subjected the adult rats, male and female F3 vinclozolin- or vehicle-lineage, stressed or non-stressed, to a battery of tests, behaviorally characterizing them, measuring hormone levels, and analyzing brain function and anatomy.

“Results showed that the effects of ancestral exposure to vinclozolin converged with stress experienced during adolescence in a sexually dimorphic manner,” the authors wrote. “Debilitating effects were seen at all levels of the phenotype, including physiology, behavior, brain metabolism, gene expression, and genome-wide transcriptome modifications in specific brain nuclei.” There were dramatic differences in the reactions between males and females, with females significantly more vulnerable to the transgenerational effects of vinclozolin on anxiety but not sociality tests.

The researchers concluded by stating that the consequences of “global contamination and stressful experiences encountered by living descendants is likely to have its own specific risk for males and females for a given spectrum of adverse outcomes. Importantly, the gene expression patterns generally support the functional behavioral and brain transcriptome differences that were observed. The implications of these results for the protection of human health and endocrine-based questions target questions of morbidity and the quality of life.”

“The most significant aspect of this paper is the striking difference between females and males at all levels, from physiology, behavior, brain chemistry, and gene expression in neural networks,” Crews says. “Females are much more sensitive when these two elements (ancestral exposure and stress during adolescence of the descendants) are combined. This, in turn, provides a new way of viewing the effects of nature (ancestral exposure) and nurture (stress during adolescence) in shaping the adult phenotype and the importance of sex differences. The latter is very much in line with the recent mandate by NIH to consider both sexes in future studies in biomedical research. Finally, it illustrates the value of considering how modern day animals whose ancestors have been exposed to EDCs perceive and respond differently to common challenges in their life history.”
COUPLES WITH HIGH CHOLESTEROL TAKE LONGER TO CONCEIVE

Couples may take longer to conceive a child when one, or both partners, has high cholesterol, according to a new study published in the *Journal of Clinical Endocrinology & Metabolism*.

Researchers led by Enrique F. Schisterman, MS, PhD, of the National Institutes of Health’s Eunice Kennedy Shriver National Institute of Child Health and Human Development in Bethesda, Md., examined the rate of pregnancies among 501 heterosexual couples trying to conceive in Michigan and Texas from 2005 to 2009. Of the couples who were part of the Longitudinal Investigation of Fertility and the Environment (LIFE) study, 347 became pregnant over the course of 12 months, 54 couples did not conceive a child, and 100 couples withdrew from the study, including some whose plans to have a child changed.

The scientists measured the total and free amounts of cholesterol in the blood of the couples and found that couples in which one or both partners had high levels of cholesterol took longer to become pregnant.

The authors concluded that serum-free cholesterol concentrations in both men and women are associated with time to pregnancy, highlighting the importance of cholesterol and lipid homeostasis for male and female fecundity. “In addition to raising the risk of cardiovascular disease, our findings suggest cholesterol may contribute to infertility,” Schisterman says. “Our results suggest prospective parents may want to have their cholesterol checked to ensure their levels are in an acceptable range.”

PEOPLE WITH T2D ACHIEVE SUPERIOR OUTCOMES WITH INSULIN PUMPS VS. INSULIN INJECTIONS

Patients with type 2 diabetes achieve better glucose control with insulin pumps than their counterparts who administer multiple daily injections, according to a study recently published in *The Lancet*.

Researchers led by Yves Reznik, MD, of the Endocrinology and Diabetes Department, CHU Côte de Nacre, in Caen Cedex, France, wrote, “Many patients with advanced type 2 diabetes do not meet their glycated haemoglobin targets, and randomised controlled studies comparing the efficacy of pump treatment and multiple daily injections for lowering glucose in insulin-treated patients have yielded inconclusive results. We aimed to resolve this uncertainty with a randomised controlled trial (OpT2mise).”

The global, randomized, controlled study analyzed 331 patients, ranging in age from 30 to 75 years, from Canada, Europe, Israel, South Africa, and the U.S. The results showed that those using insulin pumps achieved a mean A1C (average blood glucose) reduction of 1.1% compared to only a 0.4% reduction by those using multiple daily injections. This improvement in glucose control was achieved without any episodes of severe hypoglycemia. In addition, those in the insulin pump group lowered the total daily dose of insulin by more than 20%. There was no difference in weight gain between the two groups.

The authors concluded, “In patients with poorly controlled type 2 diabetes despite using multiple daily injections of insulin, pump treatment can be considered as a safe and valuable treatment option.”

PCOS LINKED TO LOW-GRADEN D INFLAMMATION DURING PREGNANCY

Women who have polycystic ovary syndrome (PCOS) are more likely to experience chronic low-grade inflammation during pregnancy than their healthy counterparts, according to research recently published in the *Journal of Clinical Endocrinology & Metabolism (JCEM)*.

Investigators led by Stefano Palomba, MD, of the Arcispedale of Santa Maria Nuova of Reggio Emilia in Reggio Emilia, Italy, evaluated 150 pregnant women who had PCOS and 150 pregnant women of about the same age and body mass index, tracking biological markers of inflammation. They found that expectant mothers with PCOS had significantly higher markers of inflammation, including white blood cell counts and C-reactive protein.

“Women who have PCOS often exhibit low-level inflammation,” Palomba says. “Our research found this state of inflammation worsens during pregnancy. Other studies have identified a connection between inflammation biomarkers and pregnancy complications such as pre-eclampsia and gestational diabetes. The abnormal inflammation seen in women with PCOS may be a factor in the development of these conditions.”
Every Thyroid Nodule Has A Tale To Tell.

And it’s a story that could help avoid surgery.

Some plot lines are simple — others can be harder to follow. When it comes to thyroid FNAs, the twists and turns are often challenging. So before you reach a conclusion on the best course of action for your patient, the Afirma® System delivers in-depth, specialized cytopathology with unique molecular analysis delivering results that can help avoid unnecessary surgeries — all from a single patient visit.

Because the more you know, the more you know what to do.

Follow the story: www.afirma.com

To speak to a representative, call 1.888.9AFirmA (1.888.923.4762)

ICE/ENDO SESSION RECORDINGS

With ICE/ENDO Session Recordings, you have access to the foremost thought leaders in endocrinology, anytime, anywhere.

ICE/ENDO 2014 SESSION RECORDINGS FEATURE

MORE THAN 100 LECTURES.

- Audio synchronized with slides
- Delivered exclusively online
- Easily downloadable mp3 files
- Includes participating clinical and translational sessions

MEMBER: $375
NONMEMBER: $575
EARLY CAREER/IN-TRAINING MEMBER: $100

To order, visit endosessions.org.
Every Thyroid Nodule Has A Tale To Tell.

And it’s a story that could help avoid surgery.

Some plot lines are simple—others can be harder to follow. When it comes to thyroid FNAs, the twists and turns are often challenging. So before you reach a conclusion on the best course of action for your patients, make sure you’re getting the full story. Afirma Thyroid FNA Analysis combines specialized cytopathology with unique molecular analysis delivering results that can help avoid unnecessary surgeries—all from a single patient visit.

Because the more you know, the more you know what to do.

Follow the story: www.afirma.com
Gathering Storm

One of the most confounding endocrine emergencies in history, thyroid storm is no longer a death sentence. Here’s a look at what’s new on the horizon in the prevention, recognition, and treatment of this once fatal malady.

By Kelly Horvath

Once approaching 100% mortality only a century ago, thyroid storm remains one of the most life-threatening endocrine emergencies at a 10% to 20% mortality rate even with advances in prevention, recognition, and treatment. Though rare, the confluence of circumstances that aggravates thyrotoxicosis so drastically leaves devastation in its wake, failing prompt treatment.

Chasing the Storm

Accounting for the persistently high mortality rate is that multiple body systems are pushed beyond their ability to compensate for the existing high thyroid hormone (TH) level. “Each of the features of uncomplicated hyperthyroidism is exaggerated to an extreme in thyroid storm, leaving not a second to lose,” says Colonel Henry B. Burch, MD, professor of medicine and chair of the Endocrinology Division of the Uniformed Services University of the Health Sciences, in Bethesda, Md., endocrinology consultant to the Office of the U.S. Army Surgeon General, and Endocrinology Service at the Walter Reed National Military Medical Center, in Bethesda.

The definitive cause, however, remains elusive. “Our best clue is a list of known precipitants associated with a sudden increase in thyroid hormone in the circulation,” Burch says (see box, p. 12). “Therefore, the key to survival is making the diagnosis.”

Making the diagnosis is not quite so straightforward, however. Patients can present with symptoms of sepsis, stimulant intoxication, or coma; go undiagnosed and, therefore, untreated; and die from multisystem decompensation. To further complicate diagnosis, there is no such thing as the “typical patient.” Although universally accepted criteria do not exist for diagnosing thyroid storm, in 1993, Burch and colleague Leonard Wartofsky, MD, professor of medicine, Georgetown University School of Medicine and editor-in-chief of the Journal of Clinical Endocrinology & Metabolism, introduced the empirically derived, Burch-Wartofsky-Point-Scale (BWPS) to assess the likelihood of thyroid storm based on quantitative clinical criteria.
“Each of the features of uncomplicated hyperthyroidism is exaggerated to an extreme in thyroid storm, leaving not a second to lose.”

— Colonel Henry B. Burch, MD, professor of medicine and chair of the Endocrinology Division of the Uniformed Services University of the Health Sciences; endocrinology consultant, Office of the U.S. Army Surgeon General, Endocrinology Service, Walter Reed National Military Medical Center, Bethesda, Md.

AT-A-GLANCE

- The cardinal manifestations of thyroid storm are fever, disproportionate tachycardia, neurologic disturbances, and gastrohepatic dysfunction.
- Recognizing and avoiding precipitants in a hyperthyroid patient is key for clinicians to prevent tipping over into a thyrotoxic crisis.
- Be alert for systemic decompensation in a patient with established thyrotoxicosis as well as for unusual presentations, such as coma or those that resemble stimulant drug intoxication or sepsis.
Yet even a single day for the clinician to arrive at the diagnosis can be too late. “You need a good clinical indication,” Burch says. These include signs of systemic decompensation, such as cardiovascular dysfunction (e.g., congestive heart failure, cardiomyopathy, cerebrovascular accident, pulmonary thromboembolism) gastrointestinal (GI) dysfunction, and central nervous system (CNS) disturbance (e.g., anxiety, psychosis, global hyperkinesis), in addition to signs and symptoms of hyperthyroidism, such as high temperature, tachycardia, hyperdefecation, and a high TH level. “Then you throw everything you’ve got in your arsenal at it.”

However, making the diagnosis is by no means simply a matter of a TH level increased beyond what constitutes hyperthyroidism or thyrotoxicosis. In fact, the BWPS awards a score independently from TH level. “It’s not a level—it’s a patient’s ability to compensate,” says Stephanie L. Lee, MD, PhD, director of the Thyroid Health Center of the Boston Medical Center, and associate professor of Medicine at Boston University School of Medicine. The degree of excess TH is not necessarily more profound than that seen in uncomplicated thyrotoxicosis, but a catalyst, such as infection or childbirth, causes the patient to decompensate and tip over into thyroid storm. “The diagnosis is clinical, based on the presence of a known precipitant plus thermodynamic dysregulation and cardiovascular, CNS, and GI dysfunction,” Lee says, “and a key point is that the fever is out of context with any existing infection.”

In 2012, Takashi Akamizu, MD, PhD, of Wakayama Medical University, Japan, and the Japanese Thyroid Association (JTA), introduced a qualitative diagnostic system. “Diagnostic Criteria, Clinical Features, and Incidence of Thyroid Storm Based on Nationwide Surveys” published recently in Thyroid, was the largest case series of thyroid storm conducted to date, comprising retrospective analysis of 282 definite and 74 suspected cases from 2004 to 2008. Their system grades thyroid storm based on the existence of one or more of the five BWPS diagnostic criteria plus thyrotoxicosis. TS1 (definite) includes CNS plus one other manifestation or three manifestations other than CNS. TS2 (suspected) includes two manifestations other than CNS or history of thyroid disease, presents with exophthalmos and goiter, and meets either of the criteria for definite cases.

“The JTA system was also largely empirically derived and includes features that mirror those in the BWPS,” Burch says. The difference lies in its sensitivity. “The JTA system may result in the selection of a slightly smaller group of patients for aggressive therapy,” Burch adds. However, the finer point remains that thyroid storm is not simply a matter of TH level — it’s a much more complicated clinical picture and a more complex etiology. Therefore, the two diagnostic systems may work most effectively in tandem. “There was a significant correlation between our diagnostic criteria and the BWPS, suggesting that both the BWPS and our criteria are helpful in diagnosing thyroid storm,” Akamizu says. “As the next obvious step, therapeutic procedures that aim for a better prognosis should be created.”

Weathering the Storm

Catching thyroid storm in the impending stage promotes the best chance of patient survival. The treatment approach is three-pronged: 1) make the diagnosis sufficiently early; 2) determine etiology and treat to reverse (e.g., antibiotics for infection); and 3) resuscitate and initiate supportive care (e.g., antipyretics, fluids, nutrition, telemetry, invasive monitoring), all of which happens concurrently. “Then there are caveats that make medical treatment very complicated,” Lee says. Reducing the TH concentration and preventing its peripheral actions must happen (optimally within 48 hours), as clinicians have known since the 1920s, but treating with iodine, which blocks both synthesis and release, can
only be done at least one hour after antithyroid drug (ATD) therapy has been instituted. Propylthiouracil (PTU) blocks the synthesis of thyroid hormones and inhibits the peripheral conversion of T4 to T3, but because of the risks associated with PTU, “you have to balance how severely T3 toxic the patient is with how severely they are decompensating, and then switch to a safer drug, such as methimazole,” Lee explains. Because the thyroid gland is unique in that it stores pre-formed TH, blocking synthesis is not enough to eliminate the excess TH; therefore, iodine must also be given. β-Blockers (e.g., propranolol) treat target organ effects. If this combination of drugs is unsuccessful in lowering thyroid hormone levels, dialysis and plasmapheresis can be undertaken as a last resort—“when your back is against the wall,” Lee adds.

Another possible complication to watch for can result from cooling the extremely hyperthermic patient with blankets or alcohol baths, which paradoxically can raise the temperature if the patient starts to shiver, Lee says.

**Storm Abatement**

With proper treatment, improvement is generally seen within two days, and full recovery is seen in one week. “Then plan for definitive therapy,” Burch says. “Once the patient is euthyroid, institute radioiodine or thyroidectomy, noting that with radioiodine, iodine given during treatment of thyroid storm must be cleared over several weeks.”

Two vital points for clinicians are to educate patients and to avoid precipitants. “Patients should be alert for fever or confusion, and clinicians should avoid abrupt ATD discontinuation (unless there is a major adverse drug effect), pretreat high-risk patients with ATDs before radioiodine therapy, and avoid surgery in thyrotoxic patients — completely correct thyrotoxicosis before elective surgery,” Burch says.

With the mortality rate still so relatively high, this confounding syndrome warrants continued research into effective treatment. As experts agree, early detection is critical, but with the physiologic complexity that thyroid storm entails, early detection may not always suffice. — EY

— Horvath is a freelance writer based in Baltimore, Md. She wrote about childhood obesity in the July issue.
SEPTEMBER 2-3
ENDOCRINE BOARD REVIEW
Whether you are seeking initial certification or recertification, the Society’s Endocrine Board Review is the premier preparatory course. Get real-time feedback on your performance during an interactive mock exam, so you can focus your studies for the best results.

SEPTEMBER 4-6
CLINICAL ENDOCRINOLOGY UPDATE
Join your colleagues at CEU for the most recent information from across the entire field of endocrinology. Get the information you need to improve your practice in a dynamic and interactive format.

REGISTER BY AUGUST 11 FOR DISCOUNTED RATES
Visit us online or call Society Services at 888.363.6762 (toll-free in the US) or 202.971.3636.

LEARN MORE AT ENDOCRINE.ORG/SF.
Now patients can enjoy the meal without worrying about the math.

Introducing the first blood glucose meter with a built-in insulin calculator,¹ the new ACCU-CHEK® Aviva Expert.

- Optimized glycemic control
- Advanced accuracy
- Precise dosing advice based on bG reading, carb count, on-board insulin, and estimated activity

Sign up to be a prescriber by talking to your ACCU-CHEK representative or by visiting accu-chek.com/expert.

Small change. Big difference.

¹ It’s the first and only meter not part of an insulin pump system to feature an insulin calculator.

ACCU-CHEK and ACCU-CHEK AVIVA EXPERT are trademarks of Roche.
© 2014 Roche. 316-53586-0614
For people with diabetes, depression acts as a magnifier. It can worsen the pain of diabetes-related neuropathy and wreak havoc on blood glucose by disturbing appetite and sapping the energy required for regular physical activity. Diverse studies such as the Diabetes and Aging Study and the Pittsburgh Epidemiology of Diabetes Complications Study suggest that people with both diabetes and depression have more than twice the risk of early mortality than people who have only diabetes.

According to a May 2013 paper published in SelfCare, roughly 11% of adults with diabetes have major depression, and 31% have clinically relevant depression, harking back to a 2001 study in Diabetes Care. With statistics like that, it’s a given endocrinologists will encounter patients with diabetes who are struggling with depression.

Yet more recent evidence, such as research presented by Lawrence Fisher, PhD, professor of family and community medicine at the University of California–San Francisco at the American Diabetes Association’s 74th Scientific Sessions in June 2014, suggests that depressive symptoms in people with diabetes often point not to clinical depression, but to diabetes distress, a separate, if similar, condition. Whereas depression is overarching, diabetes distress is about the emotional burdens of managing diabetes in particular.

“Over the past few years, we have found that many cases diagnosed as depression really were more specific to how fed up and discouraged people were with their diabetes. Sometimes people were misdiagnosed,” says William H. Polonsky, PhD, CDE, president of the Behavioral Diabetes Institute and associate clinical professor at the University of California, San Diego. “The catch is that if a patient has diabetes distress, giving that person an antidepressant is not going to make it go away.”

Considering the time constraints of an office visit, endocrinologists tend to shy away from discussing their patients’ emotional state, says Jeffrey S. Gonzales, PhD, associate professor in the Department of Medicine and the Department of Epidemiology and Population Health at the Albert Einstein College of Medicine in New York. “Endocrinologists often feel unprepared to deal with the question of depression with diabetes. They can feel like it’s opening a Pandora’s Box, or probing for things they may not have time to respond to.”

Although a diagnosis of depression should come from a mental
health professional, endocrinologists are in an excellent position to notice a decline in their patients’ emotional well-being and make a preliminary determination about diabetes distress, he adds. “It’s not that you have to fix the problem in 15 minutes, but to identify it at its most basic level.”

Screening
As with any condition, a patient’s medical history should be the first consideration in determining risk for depression, says Mark Peyrot, PhD, professor and chair of the Department of Sociology at Loyola University Maryland, in Baltimore. “The best place to start is with the idea that depression is a chronic disease like diabetes: If someone has been diagnosed with depression in the past, he or she should be closely monitored on an ongoing basis. It’s a high level of alert.”

Peyrot added that a major downturn in health, such as the development of a diabetes-related complication, is also a warning sign, particularly if there is also a simultaneous loss of diabetes control. “I wouldn’t say that patients with poor blood glucose control are at an exceptionally high risk for depression, but that depression can be one of the reasons why they have poor control.”

Ann Goebel-Fabbri, PhD, assistant professor of psychiatry at Harvard Medical School in Boston, agrees. “The hallmark of depression is lack of motivation and energy, and diabetes management requires both,” she explains. “If a patient is not meeting the optimal glycemic target and the A1c is elevated when it used to be in the healthy range, that could be a red flag.”

The Patient Health Questionnaire 9 offers a quick way to see if a patient is struggling emotionally, says Peyrot. “It’s based on diagnostic criteria for a major depressive disorder. If there is a high symptom count, the patient may qualify for a diagnosis of depression and it would be worth sending the patient to [a mental health professional] who can make that determination.”

But if the results are not clear, endocrinologists should take the time to drill down and assess the patient for diabetes distress, says Polonsky. “Ask..."
them how they feel about their diabetes, and if they can tell you one thing about their diabetes that is driving them crazy. That can give you an immediate sense of how big a problem you're looking at, and to what degree they are really grappling with diabetes distress,” he says. “People with type 1 may say they feel like they never get a break. People with type 2 may say they are frustrated with trying to lose weight. Both may say they are tired of not reaching their goals despite their best efforts.”

Tools such as the Diabetes Distress Scale 17, developed by Polonsky, Fisher, and their colleagues, contains questions designed to zero in on diabetes distress. Endocrinologists should also discuss alcohol use, says Joshua J. Neumiller, PharmD, CDE, FASCP, associate professor in the Department of Pharmacotherapy at Washington State University’s College of Pharmacy in Spokane. “People who are depressed may self-medicate with alcohol but often will not share this unless specifically asked,” he says, adding that endocrinologists may find clues in a patient’s glycemic control and could approach the subject that way. “Depending on what a patient drinks and how much, alcoholic beverages can have a considerable impact on glycaemia. Alcohol use is also associated with delayed hypoglycemic reactions. This is very much an under-recognized phenomenon and worth looking into.”

**Tools for Screening**

Tools such as the Diabetes Distress Scale 17, developed by Polonsky, Fisher, and their colleagues, contains questions designed to zero in on diabetes distress. Endocrinologists should also discuss alcohol use, says Joshua J. Neumiller, PharmD, CDE, FASCP, associate professor in the Department of Pharmacotherapy at Washington State University’s College of Pharmacy in Spokane. “People who are depressed may self-medicate with alcohol but often will not share this unless specifically asked,” he says, adding that endocrinologists may find clues in a patient’s glycemic control and could approach the subject that way. “Depending on what a patient drinks and how much, alcoholic beverages can have a considerable impact on glycaemia. Alcohol use is also associated with delayed hypoglycemic reactions. This is very much an under-recognized phenomenon and worth looking into.”

**Basic screening and a few targeted questions can provide a starting point for treatment. If the assessments strongly indicate diabetes distress, the patient may need to go no further than the endocrinologist’s office to address it.**

“With diabetes distress, the endocrinologist, diabetes nurse educator, or other clinicians in the endocrinology practice may be best qualified to talk to the patient because treatment will focus on better diabetes management,” says Gonzalez.

However, if screening points to clinical depression, then a referral to a mental health professional is in order. The challenge there is fragmentation in healthcare.

“Even if you’re a very sensitive endocrinologist who knows about depression and wants to get your patient appropriate care, insurance plans may separate mental health benefits from diabetes treatment [in a way that makes teamwork among clinicians difficult],” says Gonzalez. “It’s like chopping people up into different diseases.”

Endocrinologists or their staffs may have to do some legwork to find mental health professionals for appropriate referrals, says Goebel-Fabbri. “Be aware that many mental health providers will not have experience with diabetes, its treatments, and its goals. You may have to search for providers you can imagine your patients working with and keep a list.”

She adds that the dearth of mental health professionals knowledgeable about the finer points of diabetes care may require endocrinologists to be proactive in communicating with counselors. “Information about diabetes should come from the diabetes team,” she says. “It’s unfair to burden the patient with teaching a counselor about it. Physicians and counselors will need to talk to each other.”

— D’Arrigo is a health and science writer based in Holbrook, N.Y., and a regular contributor to Endocrine News. She wrote about treating diabetes concurrently with cancer in the July issue.
A substantial number of patients at the highest risk receiving therapy are unable to achieve LDL-C goal.

~70% of patients at the highest risk who are receiving therapy do not achieve an optional LDL-C goal of <70 mg/dL (1.8 mmol/L).**

* Data are from a 2006–2007 multinational survey, of which 2,334 patients were considered very high risk (defined as CHD plus two or more major risk factors). National Cholesterol Education Program (NCEP) Adult Treatment Panel III U.S. optional goal is <70 mg/dL (1.8 mmol/L). Countries in this analysis included the United States, Canada, Spain, the Netherlands, France, Taiwan, Korea, Brazil, and Mexico.


© 2013 Amgen Inc. All rights reserved. Not for Reproduction. 75938-R1-V1

The Endocrine Society and the International Society of Endocrinology held their joint meeting in Chicago for the first time since 1996, and ICE/ENDO 2014 attracted more registrants in the history of the Endocrine Society at over 10,000, researchers submitted a record-breaking 3,273 abstracts, and attendees sat in on more than 350 presentations.

The event, as always, featured an all-star cast of speakers, both seasoned veterans and up-and-comers, delivering a wealth of exciting new developments, groundbreaking research, and information for advancing the state of endocrinology from bench to bedside. And while it was impossible to cover everything in the massive McCormick Place, here are some of the myriad highlights from ICE/ENDO 2014.

By Derek Bagley

Another year, another annual meeting gone by, and another set of records broken. If you weren’t in Chicago in June, here’s just a small sample of the leading-edge research presented at ICE/ENDO 2014.

Diabetes Diagnosis and Management

The day before ICE/ENDO 2014 officially kicked off, attendees gathered for the Endocrine Society’s Diabetes Diagnosis and Management (DDM), a daylong, interactive workshop that focused on current issues in clinical diabetes management, namely cardiometabolic comorbidities and new treatment options, because the “prevalence of congestive heart failure in type 2 diabetes patients is quite high,” according to Darren K. McGuire, MD, MHSc, of the University of Texas Southwestern Medical Center in Dallas. And Samuel Dagogo-Jack, MD, MSc, of the University of Tennessee Health Science Center in Memphis, says that patients with type 1 diabetes have “10 times the risk for cardiovascular disease.” The challenge, then, is that diabetic patients who develop heart conditions, or are at risk of developing
these comorbidities, need to be handled differently and with greater care, and they may not always fit into neat, strict algorithms.

“We need to make good decisions based on what we know,” says Robert Eckel, MD, of the University of Colorado Anschutz Medical Campus in Aurora, in his presentation updating attendees on the ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults.

Of course, diagnosing and managing diabetes, and one of its major causes, obesity, is such a major issue in endocrinology that many of the plenary lectures, symposia, meet-the-professor sessions, and case management forums comprising ICE/ENDO 2014 were dedicated to that very issue. Diabetes and obesity once again took center stage, because the obesity epidemic is still increasing. Steven R. Smith, MD, of the Translational Research Institute for Metabolism and Diabetes in Orlando, Fla., warns that by 2030, 10% of the U.S. population will be “severely obese.” It seems like such a simple solution: Patients just need to lose weight. But as the various presentations at ICE/ENDO 2014 covering obesity proved, that solution is anything but simple.

A “Losing” Battle
The battle to help obese patients lose weight starts with getting them to eat less. Weight loss comes with eating fewer calories. The course of action usually starts conservatively, with lifestyle changes, such as a strict diet and exercise routine, and then progresses to drug therapy. New research presented at ICE/ENDO 2014 showed that the drug liraglutide, in combination with diet and exercise, led to significant weight reduction, as well as improvement in cardiovascular risk factors, based on a study of more than 3,700 overweight and obese nondiabetic adults.

Researchers led by Carel Le Roux, MD, PhD, of the Diabetes Complications Research Center at University College Dublin in Ireland, showed that on average, patients treated with 3 mg of liraglutide lost 5.4% more of their body weight than their counterparts on the placebo, achieving a total of 8%. The patients who received liraglutide also saw better improvements in their blood pressure and cholesterol. Presenting investigator David Lau, MD, PhD, of the University of Calgary, in Alberta, Canada, says that liraglutide, “as an adjunct, results in significant weight loss and cardiovascular risk improvements.”

“Current obesity options are limited,” Le Roux says. “There is a need for new treatment options for people who struggle with obesity and obesity-related diseases that can help in reducing their weight.”

But when patients don’t respond to drug therapies, surgery is the next step. Bariatric surgery, once considered extreme, is becoming more and more widely accepted as a safe and effective tool for managing obesity and even diabetes. Researchers at Brigham and Women’s Hospital in Boston showed that gastric bypass improved diabetic patients’ quality of life better than diet and exercise. Donald Simonson, MD, MPH, ScD, and his team found that weight loss surgery not only led to improvements in diabetic patients’ physical and mental health, it also led to patients reporting improvements in the adverse effects of weight on their quality of life, such as self-esteem, sex life, public distress, and work.

Roux-en-Y gastric bypass (RYGB) surgery is also an acceptable therapeutic option for reducing the risk of heart disease in obese patients with T2D, according to researchers at the Joslin Diabetes Center in Boston. Su Ann Ding, MBBS, a research fellow at the Center, and her team found that patients who had RYGB surgery lost more weight than their counterparts in a lifestyle and medical modification group. The surgical group also saw better improvements in their blood sugar control, blood pressure, and cholesterol levels.

“There is emerging evidence highlighting the potential health benefits of bariatric surgery in managing obese patients with type 2
diabetes,” says Ding. “In the past, lifestyle advice and medications provided the mainstay of treatment for this group of patients, but despite the substantial improvements in pharmacotherapy for adults with type 2 diabetes, many patients still do not achieve targeted health goals.”

**Hormones and Pregnancy**

But what about obese patients for whom surgery is not an option, but have health goals they’d like to reach? Investigators in China showed that pregnant women who engage in an intensive lifestyle modification program early, in their first trimester, gain less weight and experience fewer pregnancy complications like gestational diabetes and preeclampsia, for which obesity is a risk factor.

The study’s lead researcher, Guanghui Li, MD, PhD, of Capital Medical University in Beijing touched on the fact that obesity is now a global problem. “In the past,” she says, “Chinese people were mostly thin, but now more and more are becoming obese.” Li also pointed out that they found how hard it is for obese women to modify their lifestyles. “Healthcare providers should pay more attention to make practical and effective intervention strategies for obese pregnant women to enhance their compliance with the recommendations,” she says.

Indeed, pregnant women may experience a variety of complications during their terms, but perhaps the most devastating is miscarriage. Researchers in the U.K. may have found a way to effectively predict a woman’s risk of miscarriage by measuring blood kisspeptin levels.

Ali Abbara, MBBS, BSc, MRCP, a clinical research fellow in the Department of Investigative Medicine at Imperial College in London, presented findings of the first study showing that a single plasma kisspeptin level test during pregnancy can identify the risk for miscarriage in asymptomatic women. The investigators found that women who miscarried during the study had 60% lower kisspeptin levels than their healthy counterparts.

According to the authors of the study, miscarriage (pregnancy loss prior to 24 weeks of gestation) is the most common complication of pregnancy, affecting one in five pregnancies. Abbara says, “Being able to identify women at high risk of miscarriage may allow for improved monitoring and management of these pregnancies.” However, Abbara warned against administering kisspeptin to at-risk women to prevent miscarriage, saying that may be something available “very far in the future.”

**Endocrine-Disturbing Chemicals**

An issue that is certainly at hand right now is the call for the elimination of endocrine-disrupting chemicals (EDCs), which, as their moniker suggests, can cause damaging health effects by disrupting hormone function in the body.

Hydraulic fracturing, a process of injecting numerous chemicals and millions of gallons of water deep underground to extract natural gas, has been repeatedly shown to cause adverse health effects in people, but as research presented at ICE/ENDO 2014 showed, the endocrine-disrupting activity of those chemicals may be worse than previously thought.

Chris Kassotis, a PhD student at the University of Missouri in Columbia, and his team studied 24 fracking chemicals found in water samples collected from documented fracking spills in Garfield County, Colo. Many of the chemicals were found to block the estrogen receptor, androgen receptor, progesterone receptor, glucocorticoid receptor, and thyroid hormone receptor, all of which are necessary to stay healthy.

But many of these EDCs aren’t just found around spill sites; they’re found in consumer plastics, especially ones with hard plastics, and more and more research is pointing to their detrimental effects. The industrial chemical in question is bisphenol A (BPA), which has been shown to cause all kinds of health problems, and now research is incriminating these chemicals in even more diseases and disorders.

BPA exposure can hinder the effectiveness of a drug designed to target inflammatory breast cancer, an aggressive form of breast cancer with one of the worst survival outcomes. Gayathri Devi, PhD, an associate professor at Duke University in Durham, NC, explains that the reason for these poor outcomes is the high rate of treatment failure, and he says environment factors may explain this. Devi says, “This, to the best of our knowledge, is the first study to show BPA’s effects in altering effectiveness of a targeted drug treatment approved for use in breast cancer patients, including those with inflammatory breast cancer.”

Now that everyone’s been back home and back to work for a month or so, it’s time to start marking your calendars for the next meeting: ENDO 2015 taking place in March, in sunny San Diego, so bring sunglasses. The future of endocrinology looks bright.

— Bagley is the associate editor of Endocrine News. He wrote about competition in the April issue.
Integrated Cross-Disciplinary Approaches to the Management of Diabetic Eye Diseases

LEARNING OBJECTIVES

- Delineate an integrated cross-disciplinary referral pattern that yields the quickest patient journey with greatest improvement in quality of life.
- Assess the clinical implications of the growing diabetes epidemic, including impact on the eye care practice.
- Review the AAO guidelines for screening, treatment, and management of patients with diabetic eye diseases.
- Survey the range of available and emerging treatment options for patients with diabetic eye diseases, including safety and efficacy from clinical trials and real-world experience.
- Analyze the unique roles of ocular imaging modalities in the diagnosis and management of diabetic eye diseases.
- Determine treatment and management strategies that minimize burden on diabetic eye disease patients and their caregivers.

PARTICIPATING FACULTY

- **Seenu M. Hariprasad**, MD, University of Chicago Professor of Ophthalmology and Visual Science, Chief of Vitreoretinal Service, Director of Clinical Research, Director of Fellowship in the Diseases and Surgery of the Retina, Macula and Vitreous.
- **Zachary T. Bloomgarden**, MD, MACE, Mount Sinai School of Medicine Clinical Professor, Department of Medicine.
- **Thomas A. Albini**, MD, Associate Professor of Clinical Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine.
- **Anne L. Peters**, MD, University of Southern California, Professor of Medicine, Keck School of Medicine of USC.
- **David S. Boyer**, MD, Clinical Professor of Ophthalmology, University of Southern California/Keck School of Medicine, Los Angeles, CA, Senior Partner, Retina-Vitreous Associates Medical Group, Los Angeles, CA.
- **Carl D. Regillo**, MD, FACS, Director, Retina Service, Professor of Ophthalmology, Wills Eye Hospital, Thomas Jefferson University.
- **Darius M. Moshfeghi**, MD, Associate Professor of Ophthalmology, Director of Vitreoretinal Surgery Fellowship and Telemedicine, Byers Eye Institute, Hornigren Family Vitreoretinal Center, Dept of Ophthalmology, Stanford University School of Medicine.
- **Ronald B. Goldberg**, MD, Professor of Medicine, Division of Endocrinology, Diabetes and Metabolism, University of Miami Miller School of Medicine.
- **Louis L. Philipson**, M.D., Ph.D., FACP, Professor, Departments of Medicine and Pediatrics-Section of Endocrinology, Diabetes and Metabolism, Kovler Diabetes Center, University of Chicago.
- **John Kitchens**, M.D., Partner/Physician at Retina Associates of Kentucky.

CME CREDITS: Retina specialists and endocrinologists can earn up to 3 AMA PRA Category 1 Credits

Register at [pentavisionevents.com/DME](http://pentavisionevents.com/DME)

This program is supported by an unrestricted educational grant from Allergan and Regeneron.

ACCREDITATION: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the Joint Providership of Dannemiller and PentaVision, LLC. Dannemiller is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION: Dannemiller designates this live activity for a maximum of 3 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extension of their participation in the activity.
The “Plan B” contraceptive pill has a remarkable failure rate in larger women.

By Melissa Mapes

Physicians may want to think twice before suggesting the “Plan B” pill to patients in need of emergency contraception (EC).

The results of a large European study show that the popular form of EC, levonorgestrel 1.5 mg, (Plan B pill) loses its potency in women weighing about 165 pounds and does not work at all in women weighing 175 pounds or more. Since the average weight of a woman in the U.S. is 166.2 pounds according to the U.S. Centers for Disease Control and Prevention (CDC), women have few options but to take a gamble on the only approved form of over-the-counter emergency contraception.

The study originally set out to compare the effectiveness of different types of EC. It studied the outcomes of the levonorgestrel “morning after” pill and the ulipristal acetate pill known as “Ella” in about 2,000 women. The lead author, Anna Glasier, MD, honorary professor of Obstetrics and Gynecology at the University of Edinburgh, in Scotland, and a world-renowned expert on EC, decided the data would be more practical if it could be used to identify at-risk patients.

“Somewhere between 90% to 95% of women who take emergency contraception do not appear to be at great risk of pregnancy, so if you could work out who was genuinely at risk, it might help you as a clinician,” she explains.

She and her team conducted a meta-analysis and found a worrisome pattern: Levonorgestrel consistently failed in heavier women. Generally, levonorgestrel prevents about 50% of pregnancies that would have occurred without intervention, but when Glasier factored in weight, the effectiveness changed drastically. Women with a body mass index (BMI) of 25 or higher experienced decreased efficacy, and the pill stopped working entirely in obese women with a BMI of 30 or higher. In fact, obese women that took levonorgestrel were slightly more likely to become pregnant, 5.8%, than women who did not take EC at all, 5.6%. The number of obese women included in the study was small, but still statistically significant.

These findings elicited a change in the patient information packets of the European levonorgestrel EC that reflects the drug’s impotence in overweight and obese women. The FDA is currently reviewing the evidence and considering a change to U.S. labels, but most women are still unaware of the drug’s limited efficacy. Reports by National Public Radio state that physicians treating overweight and obese patients regularly see women who became pregnant after taking the Plan B pill.

This glaring issue was overlooked because the original research used to bring the Plan B pill to market did not focus on a representative sample of women in the
U.S. and Europe. It obtained approval from the FDA based on data from the World Health Organization in which the average BMI of participants was too small to see the effects of weight. "If you look at the first study, they reported the BMI and the mean was 22 with a standard deviation of plus or minus three. So these were not, by and large, very heavy women," Glasier explains.

More Weight, Less Efficacy
Several theories exist as to why the levonorgestrel pill fails in women over a certain weight: the dilution of the steroids in a larger blood volume; hormones becoming sequestered in fat cells; or the drug might be metabolized differently in a larger person. Yet nothing is definitive. “There is a lot of evidence that certain contraceptives are less effective in heavier women, although the studies haven’t really been of really good quality. None, including ours, have been designed to look specifically at the relationship between effectiveness and weight,” Glasier says.

Quite possibly, a larger patient simply needs a larger dose of the drug. “It is not really surprising because if you do studies on animals you dose them on a weight basis; however many milligrams per kilogram. The only reason that we don’t do that with human medication is because it would just be so horribly complicated,” Glasier continues.

The only consolation to the dismal success rate of levonorgestrel is that resulting infants are not adversely affected if a patient still becomes pregnant. Glasier insists there is no evidence for concern over a baby’s future health due to a mother ingesting Plan B or the Ella pill. That said, women should definitely be advised to consider other options.

Ella proved to be more effective than levonorgestrel regardless of weight and definitely performed better on overweight and obese women. Ella bested Plan B by half, with about 50% fewer pregnancies than those taking levonorgestrel. For both drugs, pregnancy risk is elevated by additional factors unrelated to a patient’s weight. Women who had intercourse around the time of ovulation had a fourfold increase in the likelihood of pregnancy compared to women having sex outside the window of fertility. Those who had unprotected sex after using either pill type were also more likely to get pregnant.

The IUD Option
Due to these mitigating factors, Glasier recommends the copper intrauterine device (IUD) as a first line of defense. It offers a 95% success rate as emergency contraception, making it the most effective option by far. “The big advantage, of course, is that once it’s in place you can keep it in place and it is a highly effective ongoing contraceptive until you want to get pregnant and fertility comes back to normal within a week”

Ideally, of course, women should avoid the need for EC entirely by getting a copper or Mirena IUD or a hormonal implant before an emergency arises. Glasier describes these options as “independent of compliance,” meaning that patients do not need to remember to take a daily pill or follow other such instructions. But when it is too late for preventative steps, the copper IUD is the way to go.

Unfortunately, an IUD is not available from pharmacies and a lot of women do not like the idea of having a foreign object inserted into their cervix. In the U.S., it is much more expensive than taking an emergency contraception tablet. A lack of health insurance coverage could make the costs prohibitive, and the extra steps involved may deter some patients from taking action.

The Ella pill also requires a visit to a doctor and a prescription, which prohibits some women from access. Glasier still recommends this option over Plan B if a woman is not willing or able to obtain a copper IUD.

For now the most affordable and convenient form of emergency contraception for women in the U.S. is over-the-counter levonorgestrel, and it is for sale without any warning of its ineffectuality in larger women. Those who still become pregnant will have to think of a “Plan C.”
If you’re burning the midnight oil, you’re also using a lot of electricity. Here are some simple tips to make your lab more environmentally friendly.

By Melissa Mapes

At Penn State University, lab buildings cost around $5 to $10 per square foot in utilities, while office space uses under $2 per square foot. This discrepancy is typical across universities and hospitals. An average laboratory will use three to five times more energy than an office or classroom. When you take into consideration water consumption and hazardous waste, the gap grows much larger.

Penn State saved an estimated $672,722 in operating costs after putting in place a comprehensive energy-saving project. But, unfortunately, the financial costs of running “green” programs more often outweigh the monetary savings from smaller energy bills and less trash. This has inhibited most labs from implementing similar environmental plans in the past. However, an increased consciousness about sustainability has caused green initiatives to pop up across the country and world.

The greatest progress has been made at universities like Penn. Many have established internal accountability programs to satisfy the demand among staff, faculty, and students for greener practices. Campus- or hospital-wide cooperation naturally leads to the greatest impact, but there are steps that individuals can take to reduce unnecessary waste as well.

Flip the Switch
We all know to turn off the lights when we leave a room, but there are a lot more switches to hit when exiting a lab. The impact of these many machines buzzing needlessly adds up to a significant electrical drain. Kathryn Ramirez-Aguilar, green labs program manager at the University of Colorado, Boulder, told The Scientist that a refrigerated floor centrifuge uses the same energy as a pair of flat-screen televisions when left idle at 4°C.

A lack of awareness about such facts seems to drive a large portion of excess consumption. Ramirez-Aguilar discovered that 11 diffusion pumps used to generate ultra-low pressure conditions were perpetually running in a certain lab. She put five of the pumps on timers to automatically shut off during evenings and weekends,
which saved about 58,000 kWh of electricity and one million gallons of water in a year.

Some of the largest energy consumers are freezers, specifically the ultra-low temperature (ULT) variety. An average ULT takes up 16 to 35 kWh/day, and large universities might have hundreds running across its laboratories all day long. As a secondary effect, the heat from the freezers’ motors will, in some cases, throw off the cooling system for an entire building and drive even more waste.

Experts suggest scheduled defrostings and cleaning out of superfluous samples. Labs can also share freezers to decrease the number needed and keep a careful inventory to maximize available space. Samples are often placed in ULTs when a less extreme temperature would suffice. Allen Doyle, sustainability manager at the University of California, Davis, pointed out to The Scientist that some researchers keep DNA samples at −80°C when −20° would do the trick.

Smart Inventory

Similarly, lab workers will often order things they do not need. This is especially true when it comes to chemicals. Large organizations and universities with multiple labs can share resources, but all labs should carefully record all inventory to avoid over-ordering or buying additional supplies when there are plenty of stores hidden in the stockroom.

An inefficient lab may allow buckets of chemicals to expire on the shelf while spending extra funds on unneeded replenishments if a smart tracking system is not in place. Ultimately, this leads to additional hazardous waste, as chemicals can be particularly difficult to recycle or dispose of.

The conversion to “green chemicals” can assuage the overall effects of such waste. To assist researchers in finding more environmentally friendly alternatives for their experiments, the Massachusetts Institute of Technology (MIT) tasked its Chemistry program and Environmental Health and Safety Office with developing a “purchasing wizard database.” The project is one of several funded with help from the Environmental Protection Agency’s (EPA) People, Prosperity, and the Planet grants.

Among the substitutions offered by the database, one of the most common has been ethidium bromide, a gel dye for DNA samples. Because it acts as a mutagen, this chemical can be dangerous to lab workers and causes waste removal issues. The wizard recommended Life Technologies’ SYBR Safe for DNA samples. This safer substance can be poured down the drain in many labs, though it does cost more than ethidium bromide.

Sash-ay Away

When you walk away from a fume hood, always close the sash. It provides the largest savings with the least amount of effort — up to $2,000 to $3,000 per year per hood in energy bills. Amorete Getty, co-supervisor of the LabRATS program at the University of California, Santa Barbara, claims that, “A fume hood uses the equivalent of three residential houses’ worth of electricity per year.”

The staggering consumption comes from the vacuum of air-conditioned lab air into the hood, necessitating the production of more air conditioning. The Scientist estimates that most labs require six or more air changes per hour under normal conditions, but an open sash can exponentially raise that amount. By keeping hoods closed for at least half the day, labs may be able to reduce energy needs by nearly 40%.

One easy way to remind scientists and students to close the fume hoods involves stickers. According to Getty, some laboratories have begun placing them on the side of each unit to show the amount of energy use for different heights of the sash, and report significant improvements in compliance.

Human Resources

All programs suggest a designated point person for coordinating green lab activities, from recycling to stickers. They can hold scientists and students accountable for poor practices and reward those that uphold high-efficiency standards. For laboratories that cannot afford a green project staff member, there are numerous self-checklists to assist with eco-friendly aspirations.

Although “going green” may not yet come with financial incentives for smaller operations and individuals, many researchers have come to expect and desire a greater emphasis on waste reduction, recycling, and environmental safety. The reward comes in the form of reputation and a satisfied conscience.

STAR QUALITY

The EPA’s Energy Star program has various guidelines and the steps needed to turn your lab into an energy-efficient workplace: methods to finance these strategies; products; and even case studies. A plethora of information can be found at www.energystar.gov. There are even government rebates available for using certain products.
FLARE offers senior graduate students, post-doctoral fellows and clinical fellows a multi-faceted training program:

- The FLARE Workshop — professional development and leadership training
- The FLARE Mentoring Network — online and in-person mentoring
- The FLARE Internship Program — provides exposure to the Society’s governance and leadership activities

www.endocrine.org/FLARE

Supported by the National Institute of Diabetes and Digestive and Kidney Diseases.

© 2014 Endocrine Society

PUBLISHING
with the Endocrine Society

Where Research and Recognition Meet

Did you know that the Endocrine Society Journals are among the most highly cited in the field? Or that 16,000 articles have been cited in other journals (2011 Journal Citation Report)? What about the fact that our journals receive over 12 million full-text article downloads each year?

We know authors have choices for publishing venues. We offer the combination of prestige, speed, and responsiveness. In addition to delivering exposure, the Endocrine Society journals offer other critical benefits to authors, including:

- Timely Review — average time to first decision in less than 30 days
- Fast Online Publication — accepted papers are published online weekly
- Open Access — articles made freely available 12 months after publication
- Promotion — visibility through major media outlets
- Savings — reduced publication charges for members of the Endocrine Society

Visit us online for more details on the benefits of publishing, submission guidelines and editorial policies: www.endojournals.org

© 2014 Endocrine Society
Endocrine Essentials provides rational, evidence-based approaches to clinical dilemmas in practice, as well as those found on board examinations in internal medicine or endocrinology.

NEW! Endocrine Update for General Medicine
Features the best cases from the ENDO Meet-the-Professor 2011 faculty, 216 pages
Nonmember: $95
Member: $75
Early Career/In-Training Member: $60

Cardiometabolic Self-Assessment
Adapted from our best-selling self-study program, ESAP™, 176 pages
Nonmember: $95
Member: $65
Early Career/In-Training Member: $50

Save $20 or more when you order both Essentials!
Nonmember: $150
Member: $120
Early Career/In-Training Member: $95

For more information about Endocrine Essentials visit, www.endocrine.org/endocrineessentials.
Stay Current with New Endocrine Self-Assessment Tools

Whether you’re looking for the latest information from the experts or in need of MOC points, ESAP™ 2013 and Pediatric ESAP 2013-2014 are the smart choices to improve your clinical knowledge.

- Two online modules available, each featuring 50 questions covering all areas of the ABP exam blueprint
- Discounted bundle price for purchasing two online modules and receive printed book at no additional cost
- More value for your money – Complete both modules and earn up to 32 AMA PRA Category 1 Credits™ and 40 MOC Part 2 points

For more information or to order, visit endoselfassessment.org

© 2014 Endocrine Society
You’ll notice something different at the Endocrine Society store

At the Endocrine Society’s online store and you’ll notice something different. It’s now easier to find and purchase the valuable self-assessment products, reference materials, and study guides you need in your work or practice. You’ll also find some fun gifts and Society merchandise there.

eBooks now available
Place your order today at endocrine.org/store.
Endocrine Society Calls on Congress to Stop Cuts and Keep America Safe and Healthy, Invest in Public Health

New report documents devastating impacts of deep cuts to biomedical research.

By Mila Becker

On July 15, the Endocrine Society joined with the Coalition of Health Funding (CHF), which represents more than 90 public health advocacy organizations, to call on Congress to prevent further budget cuts to federal health programs.

At a standing-room-only briefing for congressional staff, the CHF released a new report, "Faces of Austerity: How Budget Cuts Hurt America’s Health," documenting the dire consequences of Congress’ deep cuts to public health programs in recent years. The Endocrine Society contributed to the report by writing a chapter illustrating how cuts in funding for the National Institutes of Health (NIH) have significantly impeded efforts to advance diabetes research.

Broader Strategy

The report and briefing are part of a broader Society strategy to educate Congress about the impact of budget cuts on public health programs and advocate for prevention of further cuts. Just a tiny fraction of the federal budget goes toward supporting all of our nation’s public health needs — everything from preventing disease, to keeping our food and drugs safe, to ensuring that Americans have access to primary care doctors.

Flat federal funding over the last decade has reduced that small pot of money to unacceptable levels. At a time when we should be taking advantage of scientific opportunities and building on previous discoveries, the NIH is operating at a level that is 20% below its FY 2003 budget. The Society wanted to make sure congressional offices understand the impacts of its budget cuts.

Public Health Crisis

Nationally, budget cuts have forced the layoffs of more than 50,000 public health professionals who monitor and respond to virus outbreaks, immunize children and the elderly, inspect restaurants, and care for the indigent. Public health departments in 33 states and the District of Columbia have reduced their budgets. Funds for public health overall, let alone the workforce, have been eroding for nearly a decade, and while there will be some limited sequester relief in 2014, sequestration threatens public health programs in 2015 and for years to come unless Congress does something to support a balanced approach to deficit reduction.

"More than 29 million people in this country have diabetes, and we desperately need to do something about it," says Richard J. Santen, MD, Endocrine Society president. "Cuts to health programs are slowing and sometimes halting potentially life-saving research. Investing in biomedical research funding is investing in ourselves, our families, and our communities and should not be further eroded."

The “Faces of Austerity” report is available online at www.cutshurt.org.

— Becker is the senior director of Advocacy & Policy Programs, at the Endocrine Society.

"On average, a researcher has to write eight to 10 grants to get one. The likelihood of a scientist with a highly regarded grant application successfully being awarded a grant has dropped from 31.5% in 2000 to a historic low of 16.8% in 2013."

— from the Endocrine Society’s chapter of the “Faces of Austerity Report”

Take ACTION

Please help the Endocrine Society educate Congress about the value of biomedical research and the need to protect NIH from further cuts by participating in the Society’s online advocacy campaign. Simply visit the Society’s website at www.endocrine.org and click the Advocacy tab and “Contact Congress” to send a pre-written email to your congressional delegation. In addition, the Society encourages all Twitter users to tweet using the hashtag #cutshurt.
ESAP 2014 NOW AVAILABLE AND MORE VALUABLE THAN EVER

ESAP 2014 Delivers:

• Completely updated content with 120 new cases
• MOC approval from ABIM, RCPSC, and AAPA
• Fulfillment of ABIM’s new Patient Safety requirement
• Online module, hard copy reference book, conventional and SI Units
• 40 AMA PRA Category 1 Credits™

© 2014 Endocrine Society

EndoCareers TAKING YOU FROM NOW TO NEXT

VISIT OUR NEW JOB BOARD TO FIND YOUR NEXT JOB.

SET UP AN ENDOCAREERS.ORG ACCOUNT AND DISCOVER GREAT BENEFITS:

➤ Access to the best jobs
➤ Career management tools
➤ Tips for personal and professional growth

Visit endocareers.org, your source for scientific and clinical endocrinology job opportunities.

© 2014 ENDOCRINE SOCIETY
Patients rarely present with endocrine disease in isolation. Manage complex endocrine abnormalities with this timely resource featuring case histories and clinical advice on a wide-range of disorders from hyperthyroidism to impaired glucose tolerance.

Purchase online endocrine.org/store

AVAILABLE IN PRINT OR AS AN eBook
PRINT: NONMEMBER: $69  MEMBER: $56  EARLY CAREER/IN-TRAINING: $45
eBOOK: NONMEMBER: $49  MEMBER: $40  EARLY CAREER/IN-TRAINING: $30
These are some of the benefits available under the Affordable Care Act. For further information about how you and your plan are affected, contact your plan administrator.

**UNDER THE AFFORDABLE CARE ACT:**

- **80 cents of every premium dollar goes to your care, not administrative costs.**
- Choose your primary care provider and your child’s pediatrician within your network.
- No lifetime dollar limit on most benefits. Annual dollar limits will be phased out in 2014.
- No higher charges or denial of coverage because of a pre-existing condition.
- No higher co-payments or coinsurance for out-of-network emergency room visits.

**THE HEALTH INSURANCE MARKETPLACE**

[healthcare.gov](http://healthcare.gov)

The Health Insurance Marketplace was established to make buying health coverage easier and more affordable. You can:

- compare health plans
- find answers to questions
- enroll in a plan that meets your needs

**THE NEXT OPEN ENROLLMENT PERIOD:**

**NOVEMBER 15, 2014–FEBRUARY 15, 2015**
Patients have questions. We have answers.
The Hormone Health Network is your trusted source for endocrine patient education.
Our free, online resources are available at hormone.org.

**CHILDREN/YOUNG ADULTS**

- Young adults can remain on their parents’ plan up to age 26
- Many screenings, risk assessments and immunizations for children are covered:
  - congenital hypothyroidism (for newborns)
  - obesity

**WOMEN**

- 18.6 million uninsured women have new opportunities for coverage
- Women cannot be charged higher insurance premiums than men
- No referrals from primary care provider before seeking OB-GYN services from participating OB-GYN specialists
- Covered preventive services and screenings include:
  - type 2 diabetes
  - breast cancer mammography

**SENIORS**

- Seniors with Medicare receive an annual wellness preventive visit at no cost
- Other preventive services covered include:
  - diabetes screening
  - mammograms
  - bone mass measurement
- Medicare drug discounts increase yearly until the coverage gap is closed in 2020
Endocrine Society Honors Sen. Dick Durbin with Biomedical Research Champion Award

The Endocrine Society presented U.S. Senate Assistant Majority Leader Dick Durbin (D-IL) with the Biomedical Research Champion Award during a ceremony at ICE/ENDO 2014 in Chicago.

“I am honored to receive the Endocrine Society’s National Biomedical Leadership Award and to share the Society’s commitment to federal funding for biomedical research in order to help us live longer and healthier lives,” Durbin tells Endocrine News.

The award recognizes and commends members of Congress who strive to advance endocrine research and enhance public understanding of health issues pertaining to the field of endocrinology. As a member of the Senate Appropriations Committee, Durbin has worked to accelerate and secure financial support for research.

“Sen. Durbin has led the way in acknowledging the importance of biomedical research to all Americans,” says Teresa K. Woodruff, PhD, immediate past-president of the Endocrine Society. “He has fought to increase funding and create new revenue streams for the National Institutes of Health (NIH). I’m proud to honor my senator for his tireless efforts to advance research needed to identify the medical treatments of tomorrow.”

In March, Durbin introduced legislation called the American Cures Act. The proposed bill, endorsed by the Endocrine Society, would create a trust fund to support a mandatory funding stream for biomedical research. The bill would increase funding annually for the NIH, Centers for Disease Control and Prevention, Department of Defense Health Program, and Veterans Medical and Prosthetics Research Program at a rate of 5%.

Durbin noted that with diabetes and many other endocrine diseases, the biggest obstacle to better treatments and cures is not lack of science, it’s lack of money. “That is why I’ve introduced the American Cures Act,” Durbin says, “which would make federal funding for cutting-edge biomedical research less political and more predictable. I look forward to working with the Endocrine Society on this effort.”

Endocrine Society Award for Excellence in Science and Medical Journalism Awarded

Freelance journalist Cathryn Jakobson Ramin (left) received the Endocrine Society’s annual Award for Excellence in Science and Medical Journalism.

Ramin, of Mill Valley, Calif., was honored at ICE/ENDO 2014 in Chicago, for her winning article, “The Hormone Hoax Thousands Fall For.” The article was published in the October 2013 issue of More magazine.

Established in 2008, the Endocrine Society created the award to recognize outstanding reporting that enhances the public understanding of health issues pertaining to the field of endocrinology.

In her investigative article, Ramin examined the process of compounding medications and the health risks this can pose to women who are prescribed hormone therapy for hot flashes and other menopausal symptoms. Her coverage found inconsistencies in the level of hormones when identical prescriptions were filled by 12 different compounding pharmacies. She was recognized for her in-depth research and ability to clearly explain how hormones function in terms easily understood by the average reader.

The Award for Excellence in Science and Medical Journalism consists of a presentation at the Society’s awards banquet, as well as travel and accommodations to attend the Society’s Annual Meeting.

The all-day conference will explore the impact of the Patient Protection and Affordable Care Act (ACA) on patients with diabetes. Specifically, the summit will explore:

- The current state of diabetes care in the U.S., including its epidemiology, prevalence, and challenges relevant to care management.
- The cost of diabetes care and the impact on various stakeholder groups, including individual patients, third-party payers, and healthcare systems.
- Intended benefits of the ACA and how this shift in healthcare policy may impact diabetes care and outcomes.

After the summit, attendees should have a much better understanding of the humanistic and economic burden of diabetes, as well as the challenges of diagnosis, treatment, management, and prevention of long-term complications. They will also get an in-depth appraisal of the ACA—both positive and negative—from various perspectives including those of physicians, private payers, as well as patients. There will also be a vigorous discussion of future healthcare policy recommendations that favor treatment options for patients with diabetes and therapies that could prevent the disease or its progression.

Among the speakers invited to the summit are Robert Vigersky, MD, Endocrine Society past president, director, Diabetes Institute, Walter Reed National Military Medical Center; Ann Albright, PhD, RD, director, Division of Diabetes Translation, Centers for Disease Control and Prevention; Sherita Golden, MD, MHSc, associate professor of Medicine/Endocrinology and Metabolism, Johns Hopkins University; Patrick Conway, MD, MSc, deputy administrator for Innovation and Quality and Centers for Medicare and Medicaid Services; Carter Blakey, deputy director, Office of Disease Prevention and Health Promotion; Kelly Close, Close Concerns, as well as White House officials, congressional staff, key policy makers, and more.

The Ronald Reagan Building is located at 1300 Pennsylvania Avenue, NW. For more information, go to www.endocrine.org/meetings/policy-summit.
Society Journals Make the Top of the GOOGLE SCHOLAR LIST

Three of the Endocrine Society’s journals were classified as the most influential in their field, according to data released in June by Google Scholar Metrics.

The top publication in Google Scholar’s endocrinology category is The Journal of Clinical Endocrinology & Metabolism (JCEM), with Endocrinology in the number two slot, and Endocrine Reviews rated number four. The Society’s Molecular Endocrinology also made the top 20 list at number 11.

“The Editors and staff at JCEM are very proud of the Google Scholar rankings which confirm what we all believe to be the pre-eminence of JCEM amongst 120 journals in endocrinology,” says Leonard Wartofsky, MD, MACP, editor-in-chief of JCEM and professor of medicine, Georgetown University School of Medicine. “We owe that success to our readers and members who submit their manuscripts submitted leading to publication of only the very best.”

This system provides authors a quick and easy way to gauge the influence and visibility of the articles in various scientific journals. It also summarizes recent citations to a number of publications so authors can decide which journals are worthy of their research. Further, the articles are ranked in Google Scholar the same way researchers rank them: weighing the full text of each document, where it was published, who it was written by, as well as how often and how recently it has been cited in other scholarly literature.

Google Scholar ranks journals based on the h-index, which is a measurement that gauges the productivity as well as the impact of a published work by a specific scientist or author. The index is based on the author’s most cited papers as well as the number of citations the author has received in other publications.

First suggested in 2005 by Jorge E. Hirsch — the H in h-index — a physicist at the University of California in San Diego, the h-index was developed to address the perceived faults of other measurements such as simply citing the total number of papers. Hirsh felt that by just citing the volume of published works did not necessarily mean said works were of the highest quality. The h-index addresses this conundrum by including the number of citations on a given paper in other scholarly publications.

The other major measurement of journal metrics is the impact factor, which was scheduled to be released at the end of July.

— Mark A. Newman

Revamped Menopause Map Now Online

The Hormone Health Network (HHN) recently released a “new and improved” Menopause Map™, an updated interactive online tool that is essentially a one-stop source for all things relating to menopause.

“The Menopause Map can be used by women of all ages to learn more about the hormonal changes that occur during all stages of menopause, which include: preparing for menopause, premature menopause, perimenopause, menopause, and postmenopause,” says Cheretta Clerkley, director, Hormone Health Network, adding that “women who are currently on this journey should find it useful, and even fun, to use. An additional bonus is that the Network has developed tools for healthcare professionals because they are critical to helping women find the right treatment options. The healthcare professional microsite offers free tools to help medical professionals learn how to use this new interactive tool with their patients.”

Clerkley states that HHN is committed to empowering all women when it comes to menopause. “With this in mind, we recognized it was time to provide a refresh of the current map to better educate women of all the stages of menopause, to provide additional information on managing symptoms, and to inform women on where to go for peer-to-peer support resources,” she says. “This new version of the tool accomplishes these goals and enhances the women’s experience with the map, while keeping the integrity of the original Menopause Map.”

The Menopause Map can be accessed at www.menopausemap.org.
Benefits of publishing with *Hormones and Cancer*

- Easy-to-use online manuscript submission and tracking system
- Rigorous peer-review by leading experts in the field
- Rapid turnaround time
- No page charges; no page or figure limits
- Co-published with the Endocrine Society, which has more than 17,000 members

For additional information

**Journals**  [springer.com/medicine/oncology/journal/12672](http://springer.com/medicine/oncology/journal/12672)

**Submissions**  [editorialmanager.com/hoca](http://editorialmanager.com/hoca)

E  [hoca@endocrine.org](mailto:hoca@endocrine.org)

T  301.951.2603

F  301.951.2617

To view free articles, visit  [endocrine.org/journals/hormones_cancer.cfm](http://endocrine.org/journals/hormones_cancer.cfm).

*Hormones and Cancer* publishes six times per year with print issues mailing in February, April, June, August, October, and December. Published by Springer Science + Business Media, LLC, in cooperation with the Endocrine Society.
Persistent Apparent Pancreatic β-Cell Defects in Premenarchal PCOS Relatives • Laura C. Torchen, Naomi R. Fogel, Wendy J. Brickman, Rodis Paparodis, and Andrea Dunai • D1 is decreased in peripubertal FDR girls, and this decrease persists as puberty progresses. These findings suggest that β-cell dysfunction is an early defect in glucose homeostasis preceding decompensation in glucose tolerance in FDR girls. T levels were increased in FDR girls earlier than previously reported, but these changes did not persist suggesting an earlier onset of pubertal increases in glandular androgen secretion in FDR girls.

Long-Acting Progestin-Only Contraceptives Enhance Human Endometrial Stromal Cell Expressed Neuronal Pentraxin-1 and Reactive Oxygen Species to Promote Endothelial Cell Apoptosis • O. Guzeloglu-Kayisli, M. Basar, J. P. Shapiro, N. Semerci, J. S. Huang, F. Schatz, C. J. Lockwood, and U. A. Kayisli • LAPC-enhanced NPTX1 secretion and ROS generation in HESCs impair HEEC survival resulting in a loss in vascular integrity, demonstrating a novel paracrine mechanism to explain LAPC-induced AUB.

Intrinsic Expression of a Multiexon Type 3 Deiodinase Gene Controls Zebrafish Embryo Size • Cuicui Guo, Xia Chen, Huaidong Song, Michelle A. Maynard, Yi Zhou, Alexei V. Lobanov, Vadim N. Gladyshev, Jared J. Ganis, David Wiley, Rebecca H. Jugo, Nicholas Y. Lee, Luciana A Castroneves, Leonard I. Zon, Thomas S. Scanlan, Henry A. Feldman, and Stephen A. Huang • This study indicates that the embryonic deficiency of dio3, once considered only a placental enzyme, causes microsoma independent of placental physiology and raises the intriguing possibility that fetal abnormalities in human deiodination may present as intrauterine growth retardation. By mapping the gene structures and enzymatic properties of all four zebrafish deiodinases, we also identify dio3b as the first multiexon dio3 gene, containing a large intron separating its open reading frame from its selenocysteine insertion sequence (SECS) element.

Evidence of Contribution of iPLA2β-Mediated Events During Islet β-Cell Apoptosis Due to Proinflammatory Cytokines Suggests a Role for iPLA2β in T1D Development • Xiaoyong Lei, Robert N. Bone, Tomader Ali, Sheng Zhang, Alan Bohrer, Hubert M. Tse, Keshore R. Bidasee, and Sasanka Ramanadham • These observations suggest that iPLA2β-mediated events participate in amplifying β-cell apoptosis due to proinflammatory cytokines and also that iPLA2β activation may have a reciprocal impact on ER stress development. They raise the possibility that iPLA2β inhibition, leading to ameliorations in ER stress, apoptosis, and immune responses resulting from LPC-stimulated immune cell chemotaxis, may be beneficial in preserving β-cell mass and delaying/preventing T1D evolution.

ERβ- and Prostaglandin E2-Regulated Pathways Integrate Cell Proliferation via Ras-Like and Estrogen Regulated Growth Inhibitor in Endometriosis • D. Monsivais, M.T. Dyson, P. Yin, J.S. Coon, A. Navarro, G. Feng, S.S. Malpani, M. Ono, C.M. Ercan, J.J. Wei, M.E. Pavone, E. Su, and S.E. Bulun • Overall, we demonstrated that E2/ERβ and PGE2, integrate at RERG leading to increased endometriotic cell proliferation and represents a novel candidate for therapeutic intervention.

Endogenous ω-3 PUFAs Production Confers Resistance to Obesity, Dyslipidemia, and Diabetes in Mice • Jie Li, Fanghong R. Li, Dong Wei, Wei Jia, Jing X. Kang, Maja Stefanovic-Racic, Yifan Dai, and Allan Z. Zhao • This study shows that endogenous conversion of ω-6 to ω-3 PUFAs via fat-1 strongly protects against obesity, diabetes, inflammation, and dyslipidemia, and may represent a novel therapeutic modality to treat these prevalent disorders.

Comprehensive Overview of the Structure and Regulation of the Glucocorticoid Receptor • Sofie Vandevyver, Lien Dejager, and Claude Libert • In this review, we summarize recent knowledge on the distinct GR isoforms and the processes that generate them. We also review the importance of all known transcriptional, post-transcriptional, and post-translational modifications, including the regulation of GR by microRNAs. Moreover, we discuss the crucial role of the putative GR-bound DNA sequence as an allosteric ligand influencing GR structure and activity. Finally, we describe how the differential composition and distinct regulation at multiple levels of different GR species could account for the wide and diverse effects of glucocorticoids.

Endocrine Scintigraphy with Hybrid SPECT/CT • Ka Kit Wong, Lorraine M. Fig, Ebah Youssef, Alice Ferretti, Domenico Rubello, and Milton D. Gross • The integration of function depicted by scintigraphy and anatomy with CT has synergistically improved the efficacy of nuclear medicine imaging across a broad spectrum of clinical applications, that include some of the oldest imaging studies of endocrine dysfunction.
Join us for the fourth international summit of Prenatal Programming and Toxicity (PPTOX) – a premiere conference series dedicated to cutting-edge discussion of environmental hazards during early life and long-term consequences.

**KEY DATES:**
- ADVANCED REGISTRATION DEADLINE – MONDAY, AUGUST 18
- ABSTRACT SUBMISSION DEADLINE – TUESDAY, SEPTEMBER 2
- HOUSING DEADLINE – MONDAY, OCTOBER 6

For program details and registration deadlines, visit endocrine.org/PPTOX.
ENSURE QUALITY CARE WITH
CLINICAL PRACTICE GUIDELINES
FROM THE ENDOCRINE SOCIETY

NEW! Get the latest scientific evidence and best practice advice with our guideline Pheochromocytoma and Paraganglioma.

Chaired by Dr. Jacques Lenders, Pheochromocytoma and Paraganglioma provides actionable recommendations for practicing physicians on biochemical testing for diagnosis, imaging studies, genetic testing, perioperative medical management, and surgery.

The Society’s Clinical Practice Guidelines are developed by a team of experts, through a rigorous and multi-step, peer review process to ensure the highest quality, evidence-based recommendations.

To purchase a hard copy, visit endocrine.org/store.
Download a free copy of the guideline at endocrine.org/CPG.

© 2014 Endocrine Society

LET ENDOCAREERS® HELP YOU WITH ALL OF YOUR CAREER DEVELOPMENT NEEDS.

▶ EndoCareers® Magazine
—a quarterly publication for early career professionals

▶ EndoGrants Central™
—listing available grants of interest to the endocrine community

▶ Early Career Awards
—more than 400 are distributed annually

▶ Job Board
—find your next opportunity

▶ Recruitment Advertising
—find the perfect new employee

▶ And much more!

Discover all of the products, services, and funding opportunities available at ENDOCAREERS.ORG

© 2014 ENDOCRINE SOCIETY
If you are interested in submitting classified advertising to Endocrine News, please contact Christine Whorton at endocareers@endocrine.org or 800-361-3906.

PRESBYTERIAN HEALTHCARE SERVICES, Albuquerque, NM:
Presbyterian Healthcare Services is seeking BE/BC Endocrinology trained physicians to join Presbyterian Medical Group and our well established Endocrinology providers. Our medical group employs more than 600 primary care and specialty providers and is the fastest growing employed physician group in New Mexico. Presbyterian Healthcare Services is a locally owned, not-for-profit organization based in Albuquerque. Our integrated healthcare system includes eight hospitals in seven New Mexico cities, a medical group, multispecialty clinics and a health plan (over 400,000 members). We have been proudly providing care to New Mexicans for 105 years. In addition to a guaranteed base salary we also offer a sign on bonus, incentive bonus, malpractice, relocation, house hunting trip, health, dental, vision, 403(b) w/ contribution from PHS 457(b), short & long term disability, CME allowance, etc. Albuquerque thrives as New Mexico’s largest metropolitan center with a population of 700,000. Albuquerque has been listed as one of the best places to live in the United States by Newsweek, U.S. News & World Report, Money and Entrepreneur Magazines! Albuquerque is considered a destination city for most types of outdoor activities with 310 days of sunshine. Albuquerque is recognized as one of the most culturally diverse cities in the country. Its ethnic diversity is carried into its architecture, art, music, dance and cuisine. A truly diverse and multicultural city, Albuquerque offers you and your family a great variety of activities and entertainment including national theater productions, sporting events, golf courses ranked among the best in the country, the largest hot air balloon festival in the US, American Indian Cultural activities and much more. For more information, e-mail Kelly Herrera at kherrera@phs.org or call 1-505-923-5662. H1B Opportunity.

A UNIQUE AND EXCITING ACADEMIC FACULTY POSITION AVAILABLE: Division of Endocrinology and Metabolism at the University of Texas Health Science Center at San Antonio is seeking a full time or part time Endocrinologist at the Assistant or Associate Professor level to contribute to our growing clinical practice, research activities and teaching. This is an exceptional academic opportunity for a junior faculty member who is self-motivated and excited about patient care, teaching and learning and/or ready for research independence. Candidates with strong interest/expertise in metabolic bone disease, thyroid, adrenal and/or pituitary diseases are encouraged to apply. Opportunities to do clinical research are available. The candidate must be BC/BE in Endocrinology & Metabolism. San Antonio is known for its low cost of living and rich bicultural heritage. Please send updated curriculum vitae and names of three references to: Jan M. Bruder, M.D., Dept. of Medicine/Endocrinology, 7703 Floyd Curl Dr., MSC 7877, San Antonio TX 78229-3900. All faculty appointments are designated as security-sensitive positions. The University of Texas Health Science Center at San Antonio is an Equal Employment Opportunity/Affirmative Action Employer.

PIKEVILLE MEDICAL CENTER
PIKEVILLE, KY

Now seeking an
ENDOCRINOLOGIST
Hospital employed position
Must be BC/BE

Approximately 20 patients seen daily
State-of-the-art equipment
Offices within a brand new $150 million clinic building
BC-ADM Nurse Practitioner with 20 years experience
In-office procedures
Services complementing the practice include:
- Radiology
- Ophthalmology
- Nephrology
- Bariatric Surgery
- Nutrition and Diabetes Education

We offer a generous salary, full support staff and an excellent comprehensive benefits package.

For more information, contact:
Physician Recruitment
ashley.mccoy@pikevillehospital.org
606-218-4915
606-794-8548

Pikeville Medical Center is an equal opportunity employer
Geisinger Health System (GHS) is seeking Endocrinologists for two locations:

- Endocrinology at Geisinger Wyoming Valley Medical Center (GWV), Wilkes-Barre, Pa.
- The Endocrinology team at Geisinger-Patton Forrest, State College, Pa.

About the Position at GWV

- Join a team of 3 Endocrinologists, 2 Nurse Practitioners and 3 Certified Diabetes Educators, and is positioned for additional growth
- Work collaboratively with Geisinger’s community practice network to enhance diabetes care, as well as to work with multiple subspecialties to enhance inpatient care
- Opportunities for clinical practice include serving as investigator on diabetes clinical trials, US-guided Thyroid Fine Needle Aspiration Biopsies, Continuous Glucose Sensors and Bone Density interpretation
- Engage in clinical mentoring and educational programs for medical students and family medicine residents on the GWV campus, as well as internal medicine residents on rotation at GWV

About the Position at Geisinger–Patton Forrest

- Join a growing endocrinology department in a thriving, multi-specialty group practice, located in a progressive university town
- Provide 100% endocrinology subspecialty outpatient care and inpatient consultations
- Provide consultative care at Mt. Nittany Medical Center, State College, Pa., and Lewistown Hospital, Lewistown, Pa.

Geisinger Health System serves nearly 3 million people in Northeastern and Central Pennsylvania and has been nationally recognized for innovative practices and quality care. A mature electronic health record connects a comprehensive network of 5 hospitals, 43 community practice sites and more than 1,000 Geisinger primary and specialty care physicians.

Discover for yourself why Geisinger has earned national attention as a visionary model of integrated healthcare. For more information, please visit geisinger.org/careers or contact: John W. Kennedy, MD, Endocrinology Department Director, Geisinger Health System c/o Kathy Kardisco, Department of Professional Staffing, at 800.845.7112 or kkardisco@geisinger.edu.
Did you know that the Endocrine Society Journals are among the most highly cited in the field? Or that 16,000 articles have been cited in other journals (2011 Journal Citation Report)? What about the fact that our journals receive over 12 million full-text article downloads each year?

We know authors have choices for publishing venues. We offer the combination of prestige, speed, and responsiveness. In addition to delivering exposure, the Endocrine Society journals offer other critical benefits to authors, including:

- **Timely Review** — average time to first decision in less than 30 days
- **Fast Online Publication** — accepted papers are published online weekly
- **Open Access** — articles made freely available 12 months after publication
- **Promotion** — visibility through major media outlets
- **Savings** — reduced publication charges for members of the Endocrine Society

Visit us online for more details on the benefits of publishing, submission guidelines and editorial policies: www.endojournals.org
Your Partner in Patient Education

The Hormone Health Network joins Society members, health care professionals, patients, and the public in meaningful, informed discussions about hormones and health. Available in both English and Spanish, the Network’s bilingual fact sheet series provides patients with accurate, expert-reviewed information on more than 80 endocrine-related topics in an easy-to-understand format.

Visit www.hormone.org and sign up for Hormone Hotline, our monthly e-update, to get the latest news on Hormone Health Network publications and events.

Together, we can move patients from educated to engaged, from informed to active partners in their healthcare.

Engaging and educating more than 2 million people each year!
SEPTEMBER 2-3
ENDOCRINE BOARD REVIEW
Whether you are seeking initial certification or recertification, the Society’s Endocrine Board Review is the premier preparatory course. Get real-time feedback on your performance during an interactive mock exam, so you can focus your studies for the best results.

SEPTEMBER 4-6
CLINICAL ENDOCRINOLOGY UPDATE
Join your colleagues at CEU for the most recent information from across the entire field of endocrinology. Get the information you need to improve your practice in a dynamic and interactive format.

REGISTER BY AUGUST 11 FOR DISCOUNTED RATES
Visit us online or call Society Services at 888.363.6762 (toll-free in the US) or 202.971.3636.

LEARN MORE AT ENDOCRINE.ORG/SF.